| Trial ID: | L5445 |
| Source ID: | NCT00687999
|
| Associated Drug: |
Pegylated Interferon Alpha And Ribavirin
|
| Title: |
NIDDM and IR in Combination Therapy for CHC
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Hepatitis C|Insulin Resistance
|
| Interventions: |
DRUG: pegylated interferon alpha and ribavirin
|
| Outcome Measures: |
Primary: Sustained virological response (SVR) rate, HCV RNA seronegative by PCR throughout 24-week off-treatment period; biochemical, virological and histological characteristics of CHC patients; HOMA-IR change after combination therapy, 18 months |
|
| Sponsor/Collaborators: |
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital | Collaborators: National Science Council, Taiwan
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
400
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-12
|
| Completion Date: |
2008-06
|
| Results First Posted: |
|
| Last Update Posted: |
2009-08-06
|
| Locations: |
Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT00687999
|
